Jump to: Uses | Method | Category | Reference | Pre-test Info | Specimen | Storage | Stability | Report | More Details
Uses: Tumor marker for diagnosing lung cancer. Monitoring the course of Non-small cell lung cancer (NSCLC) & course monitoring in Myoinvasive Bladder cancer
Method: Quantitative ELISA, Electrochemiluminescence, Immunoradiometric Assay
Category: Cancer, Oncology
Reference: Normal < 3.30 ng/mL, Elevated > 3.30 ng/ml
Pre-test Information: Provide a brief clinical history. No special preparation required
Specimen Collection: 2 mL (0.5 mL min.) serum from 1 SST. Ship refrigerated or frozen. Allow serum specimen to clot completely at room temperature. Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to plain Red tube.
Storage: Refrigerated
Stability: Stability Room 2 hrs
Stability Refrigerated 4 weeks
Stability Frozen 2 months (avoid repeated freeze/thaw cycles)
Report Availability: Same day – 8 days
More Details: CYFRA 21–1 is a sensitive and specific tumor marker of non-small-cell lung cancer (NSCLC), especially of squamous cell subtype. It also reflects the extent of the disease and has an independent prognostic role along with performance status and disease stage in NSCLC. In addition, detection of serum CYFRA 21–1 allows for the identification of high-risk patients that may benefit from adjuvant chemotherapy and enables the early detection of progressive disease in recurrent NSCLC. Additionally, CYFRA 21–1 has been described as a useful marker for oesophagal squamous cell carcinoma and for therapy monitoring of bladder cancer. This test is not recommended for the primary diagnosis of Lung cancer. Patients receiving Biotin therapy in high doses should not be tested for at least 8 hours after the last dose. Levels greater than 30 ng/mL are highly indicative of Primary Bronchial carcinoma. Increased Levels are also found in Non-Small cell carcinoma lung, Acute pneumonia, Tuberculosis, Interstitial lung disease, Liver cirrhosis & Renal failure.